# Carotid Restenosis: Incidence, Pathophysiology and Therapeutic Options

**Authors:** Claudio Bianchini Massoni, Laura Pauletti, Antonio Freyrie

PMC · DOI: 10.3390/jpm16020091 · 2026-02-04

## TL;DR

This paper discusses carotid restenosis, a common complication after carotid treatments, and explores its causes and treatment options.

## Contribution

The paper provides an updated overview of the incidence, pathophysiology, and therapeutic strategies for carotid restenosis.

## Key findings

- The 2-year restenosis rate after carotid treatments is 6–12%.
- Inflammation processes are linked to both early and late restenosis.
- Treatment options include lifestyle changes, medical therapy, and personalized procedural techniques.

## Abstract

Restenosis after carotid endarterectomy and carotid artery stenting remains the main complication after both surgical and endovascular treatment of carotid stenosis, with a 2-year restenosis rate of 6–12%. Complex inflammation processes are the cause of early (<2 years) and late (>2 years) restenosis and principal systemic risk factors are female gender, hypertension, diabetes, dyslipidemia, and smoking. Non-procedural treatment includes lifestyle modifications and best medical therapy. The procedural treatment, considered mostly for symptomatic patients, includes different open and endovascular techniques. The management should be personalized according to patient and plaque characteristics.

## Linked entities

- **Diseases:** carotid stenosis (MONDO:0001612), diabetes (MONDO:0005015), dyslipidemia (MONDO:0002525)

## Full-text entities

- **Genes:** MBL2 (mannose binding lectin 2) [NCBI Gene 4153] {aka COLEC1, HSMBPC, MBL, MBL2D, MBP, MBP-C}, CLU (clusterin) [NCBI Gene 1191] {aka AAG4, APO-J, APOJ, CLI, CLU1, CLU2}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}
- **Diseases:** cervical lesions (MESH:D002575), cranial nerve injury (MESH:D020209), neurological cerebral symptoms (MESH:D009461), stenosis (MESH:D003251), stroke (MESH:D020521), obese (MESH:D009765), bleeding (MESH:D006470), restenotic lesion (MESH:D009059), cardioembolism (MESH:D000083262), angina (MESH:D000787), calcification (MESH:D002114), vessel injury (MESH:C536223), ischemic (MESH:D002545), plaque rupture (MESH:D012421), diabetes (MESH:D003920), dyslipidemia (MESH:D050171), fibromuscular hyperplasia (MESH:D005352), CAS (MESH:D016893), hematoma (MESH:D006406), fibrosis (MESH:D005355), inflammation (MESH:D007249), injury to (MESH:D014947), CCA (MESH:C536211), Intimal hyperplasia (MESH:D006965), prolapse (MESH:D011391), thromboembolic (MESH:D013923), TIA (MESH:D002546), embolic (MESH:D004617), amaurosis fugax (MESH:D020757), weight (MESH:D015431), microtrauma (MESH:D000070617), myocardial infarction (MESH:D009203), atherosclerosis (MESH:D050197), CBA (MESH:D054549), death (MESH:D003643), hypertension (MESH:D006973), thrombosis (MESH:D013927), Carotid Restenosis (MESH:D023903), Carotid Artery (MESH:D002340)
- **Chemicals:** cholesterol (MESH:D002784), vitamin C (MESH:D001205), aspirin (MESH:D001241), paclitaxel (MESH:D017239), PTFE (MESH:D011138), ezetimibe (MESH:D000069438), Dacron (MESH:D011093), Lipid (MESH:D008055), Cilostazol (MESH:D000077407), Nicotine (MESH:D009538), homocysteine (MESH:D006710), ticagrelor (MESH:D000077486), Clopidogrel (MESH:D000077144), CAS (-)
- **Species:** Bos taurus (bovine, species) [taxon 9913], Homo sapiens (human, species) [taxon 9606]

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12941902/full.md

---
Source: https://tomesphere.com/paper/PMC12941902